| 中文名稱:CDH3抗體 | 英文名稱:Rabbit Polyclonal CDH3 Antibody |
| 品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
| 保存條件: Stored at -20°C for 3587 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
| 重組: 否 | 應用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
| 種屬反應性: Human,Mouse,Rat | 宿主: Rabbit |
| 偶聯(lián)物: 無 | 靶點: CDH3 |
| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨詢技術(shù) | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
| FCM | 咨詢技術(shù) | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CDHP; HJMD; PCAD |
| WB Predicted band size | 91 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CDH3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-5: MCF7, HUVEC, HepG2, 293T, K562 cell lysates, Primary antibody: P07526(CDH3 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute
The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P07526(CDH3 Antibody) at dilution 1/80. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07526(CDH3 Antibody) at dilution 1/80. (Original magnification: ×200)
以下是關(guān)于CDH3抗體的3-4篇參考文獻示例(注:部分為模擬內(nèi)容,實際文獻需通過學術(shù)數(shù)據(jù)庫核實):
---
1. **文獻名稱**:*Targeting P-cadherin (CDH3) in triple-negative breast cancer using a novel monoclonal antibody*
**作者**:Freitas, N. et al.
**摘要**:該研究開發(fā)了一種靶向CDH3(P-cadherin)的單克隆抗體,證實其在三陰性乳腺癌中可抑制腫瘤細胞遷移和侵襲,并通過阻斷CDH3介導的細胞間黏附增強化療敏感性。
2. **文獻名稱**:*CDH3 as a therapeutic target in pancreatic cancer: Preclinical evaluation of an antibody-drug conjugate*
**作者**:Lee, S. et al.
**摘要**:研究構(gòu)建了CDH3抗體偶聯(lián)藥物(ADC),在胰腺癌模型中顯示顯著抗腫瘤活性,通過內(nèi)化抗體靶向降解CDH3高表達的癌細胞,并減少轉(zhuǎn)移。
3. **文獻名稱**:*Diagnostic potential of anti-CDH3 autoantibodies in gastric cancer early detection*
**作者**:Wang, Y. et al.
**摘要**:探討了CDH3自身抗體作為胃癌生物標志物的潛力,發(fā)現(xiàn)患者血清中抗CDH3抗體水平升高,與早期腫瘤進展相關(guān),可能用于無創(chuàng)診斷。
4. **文獻名稱**:*CDH3 inhibition reshapes the tumor microenvironment via antibody-mediated phagocytosis*
**作者**:Garcia, M. et al.
**摘要**:證明抗CDH3抗體通過激活巨噬細胞的抗體依賴性細胞吞噬(ADCP)作用,重塑腫瘤微環(huán)境,抑制CDH3高表達的結(jié)直腸癌生長。
---
建議通過PubMed或Google Scholar檢索具體文獻,關(guān)鍵詞如“CDH3 antibody therapy”“P-cadherin monoclonal antibody”等。
CDH3 (Cadherin-3), also known as P-cadherin, is a calcium-dependent cell adhesion glycoprotein belonging to the type I classical cadherin family. It plays a critical role in maintaining tissue architecture by mediating homophilic cell-cell interactions, particularly in epithelial and endothelial layers. Structurally, CDH3 contains five extracellular cadherin repeats (EC domains), a transmembrane region, and a conserved cytoplasmic domain that interacts with catenins to link the actin cytoskeleton.
CDH3 is selectively expressed in normal tissues such as the placenta, epidermis, mammary glands, and developing tissues, but its overexpression is frequently observed in aggressive cancers, including breast, lung, pancreatic, thyroid, and melanoma. This dysregulation is associated with enhanced tumor progression, metastasis, and poor prognosis, likely due to its role in promoting epithelial-mesenchymal transition (EMT) and cell migration.
CDH3 antibodies are immunological tools designed to detect and study the expression, localization, and function of CDH3 in biological samples. They are widely used in research applications like immunohistochemistry (IHC), Western blotting, and flow cytometry. Therapeutic interest in CDH3 has grown, with antibodies being explored for targeted drug delivery (e.g., antibody-drug conjugates) or as diagnostic biomarkers for cancer. However, its complex role in both normal physiology and disease necessitates careful evaluation to avoid off-target effects in clinical settings.
| 成立日期 | 2024-06-24 (3年) | 注冊資本 | 50萬(元) |
| 員工人數(shù) | 1-10人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
| 主營行業(yè) | 中間體,化學試劑 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務 |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| ¥1600.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-07-29 | |
| 詢價 |
VIP4年
|
武漢佰樂博生物技術(shù)有限公司
|
2026-07-29 | |
| ¥3500 |
VIP3年
|
北京百普賽斯生物科技股份有限公司
|
2026-06-30 | |
| ¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |